YOLFTbeta
31

Biodyne Co. Ltd.

314930 · KQ · Healthcare / Medical Instruments & Supplies

5,560.00KRW-90.00 (-1.59%)

Price History

Full chart

Market Stats

Previous Close5,650.00
Open5,600.00
Day Range5,410.00 – 5,800.00
52-Week Range6,460.00 – 16,860.00
Volume16.57K
Market Cap203.68B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.08
50-Day Avg7,475.40
200-Day Avg10,738.65

About

Biodyne Co., Ltd. engages in the development, manufacture, and sale of liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis in South Korea. The company offers PATHPLORER solution, which preserves and fixes the collected cells; PATHPLORER LBC system, an equipment for processing liquid cytology samples for cancer diagnosis. It exports its products to Japan, Russia, Portugal, Thailand, and internationally. The company was founded in 1999 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOWook-bin Im
  • Employees0
  • Headquarters24-4, Achasan-ro 5-gil, Seoul, South Korea, 04793, Korea
  • Websitehttps://www.biodyne.asia

Leadership

  • Wook-bin ImSupreme Leader & C.E.O. · b. 1974
  • Mr. Geunho YangFinance Leader & CFO · b. 1972
  • Mr. Ja-min LeeHead of Research Institute · b. 1975
  • Kanis ChowLeader & C.Q.O
  • YuRa KoEnhancer Leader & C.H.O.
  • GyeongEun JangInsight and Action Team Leader & CQO

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.77B4.09B3.67B3.76B12.21B4.09B5.27B7.03B
Growth (%)-+8.44%-10.23%+2.51%+224.46%-66.51%+28.93%+33.32%
Cost of Revenue1.78B2.91B3.19B3.26B2.91B3.40B2.83B2.56B
Gross Profit1.99B1.18B479.17M498.56M9.31B684.27M2.44B4.47B
Gross Margin52.74%28.74%13.05%13.25%76.21%16.74%46.25%63.57%
Operating Expense1.64B2.87B2.31B2.84B2.62B2.74B4.17B3.82B
Operating Income347.96M-1.70B-1.83B-2.34B6.68B-2.05B-1.73B652.26M
Operating Margin9.23%-41.52%-49.75%-62.25%54.73%-50.16%-32.82%9.28%
EBITDA----8.92B444.71M1.48B2.16B
EBITDA Margin----73.08%10.88%28.09%30.72%
Net Income-1.38B-2.03B-4.45B-10.86B5.61B-991.76M10.77M851.59M
Net Income Margin-36.60%-49.55%-121.34%-288.50%45.96%-24.26%0.20%12.12%
R&D--445.39M390.67M412.33M382.73M251.76M272.16M
R&D as % of Total Revenue--12.13%10.38%3.38%9.36%4.78%3.87%
Interest Expense00589.50M215.23M443.00K223.00K174.00K160.00K
Interest Expense % of Total Revenue0.00%0.00%16.06%5.72%0.00%0.01%0.00%0.00%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.92B23.25B25.24B45.82B45.41B43.99B44.35B44.94B
Total Liabilities12.49B16.68B18.24B7.32B1.26B603.91M1.15B870.68M
Total Equity422.25M6.58B7.00B38.50B44.16B43.38B43.20B44.07B
Cash1.29M53.00K2.98B2.78M2.86M9.73B4.83B12.98B
Total Debt-6.86B8.92B-----
Net Debt-6.32B3.88B-----

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow530.11M4.20B115.72M-504.73M2.59B405.03M877.41M830.26M
Investing Cash Flow-879.22M-12.52B-333.74M-15.36B-1.36B-1.67B-5.91B-
Financing Cash Flow-7.59B2.81B22.11B-10.24M192.54M-203.86M-
Capital Expenditure782.36M11.06B875.57M836.05M1.43B669.73M539.15M5.64B
Free Cash Flow---680.38M-1.37B1.02B-264.70M338.26M-4.81B
FCF to OCF---587.94%271.54%39.58%-65.35%38.55%-578.93%

Earnings

Report DateMar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------
EPS Actual-332.64-3.35-15.57-17.67-2.852.2611.45179.754.44-9.36-8.77-19.31-6.885.09-13.0215.03-14.75-3.530.4446.735.27-10.96
Surprise----------------------
Timing----------------------

Key Statistics & Ratios

Market Cap203.68B
Enterprise Value181.86B
Trailing P/E0.00
Forward P/E0.00
Price / Sales35.28
Price / Book4.47
Revenue (TTM)5.77B
Gross Profit (TTM)3.52B
EBITDA1.35B
Profit Margin21.18%
Operating Margin-115.89%
Return on Equity3.30%
Return on Assets-2.09%
Shares Outstanding29.48M
Shares Float16.91M
Beta1.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Feb 28, 20245:1